Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib and Serplulimab in NF2-Related Tumors
NCT07708285Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib, serplulimab in neurofibromatosis type 2 (NF2), sponsored by Beijing Tiantan Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
luvometinibserplulimab
03
Conditions
neurofibromatosis type 2 (NF2)
Beyond the preview
Go deeper on NCT07708285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708285.